Astrana Health (ASTH) Expected to Release Earnings on Thursday

Astrana Health (NASDAQ:ASTH) is expected to be releasing its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Astrana Health to announce earnings of $0.4573 per share and revenue of $1.02 billion for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 5:30 PM ET.

Astrana Health (NASDAQ:ASTH) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.46. Astrana Health had a net margin of 1.05% and a return on equity of 10.30%. The business had revenue of $972.52 million for the quarter, compared to analysts’ expectations of $985.62 million. During the same quarter in the previous year, the business posted $0.19 earnings per share. The business’s revenue was up 48.5% compared to the same quarter last year. On average, analysts expect Astrana Health to post $1.36 EPS for the current fiscal year and $1.93 EPS for the next fiscal year.

Astrana Health Trading Up 1.0%

Shares of ASTH opened at $36.88 on Tuesday. The company’s fifty day simple moving average is $37.04 and its 200-day simple moving average is $33.80. The company has a market cap of $2.06 billion, a P/E ratio of 21.70 and a beta of 1.03. The company has a current ratio of 1.23, a quick ratio of 1.23 and a debt-to-equity ratio of 1.05. Astrana Health has a twelve month low of $18.08 and a twelve month high of $51.60.

Analysts Set New Price Targets

Several brokerages recently commented on ASTH. Barclays upped their price target on shares of Astrana Health from $50.00 to $53.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Wall Street Zen downgraded shares of Astrana Health from a “buy” rating to a “hold” rating in a research note on Sunday, August 16th. Weiss Ratings reissued a “hold (c)” rating on shares of Astrana Health in a research note on Thursday, August 27th. Oppenheimer initiated coverage on Astrana Health in a research report on Tuesday, September 15th. They set an “outperform” rating and a $53.00 target price for the company. Finally, Truist Financial upped their target price on Astrana Health from $47.00 to $55.00 and gave the company a “buy” rating in a research note on Monday, August 10th. Eight analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $49.88.

Astrana Health Company Profile

Astrana Health, Inc (NASDAQ: ASTH), formerly known as Apollo Medical Holdings, is a healthcare enablement company focused on helping providers and health plans deliver coordinated, value-based care. The company combines physician networks, care-management capabilities, technology and data analytics to support improved clinical outcomes and more efficient healthcare delivery.

Astrana Health’s services include population health management, physician practice support, utilization management, care coordination and clinical analytics.